UPDATE: Deadline extended to November 17 at 11:59 PM ET.
Thanks to the generous support of our patients, families, caregivers, corporate supporters, and the many friends of the Mesothelioma Applied Research Foundation, we are pleased to announce that the 2023 research funding grant cycle is now open and accepting pre-application letters of intent (LOI) until 11:59 PM ET Friday, November 10, 2023. Our research grant program offers $100,000 grants for two years ($50,000 per year). Please read below before applying.
Additional information to be included in the LOI:
- All applications need to focus on pleural and/or peritoneal mesothelioma and should address at least one of the 2023 Areas of Interest (listed below).
- All projects must be feasible within the timeline and budgetary constraints of the current LOI.
- All other funding, overlapping and/or supplemental funding, for the proposed project should be disclosed as part of the application.
- Junior investigators with an interest in a carrier focus in mesothelioma are strongly encouraged to apply to this RFA. As part of their application, they should identify an established mesothelioma researcher as their mentor and provide a career development and mentorship plan in the context of their application.
2023 Areas of Interest (not listed in priority order):
- Novel therapies for mesothelioma for both pleural and peritoneal, especially targeted therapies, combination immunotherapy, cellular therapy, and virotherapy.
- Health-related quality of life assessment incorporating the social determinants of health (SDOH) specific to mesothelioma patient care, side effect management, mental health care impact on patient and/or caregiver outcomes, and other related topics.
- Novel strategies for screening and early detection.
- Novel strategies for risk assessment and prognosis stratification.
- Immune mediated complications of immunotherapy in mesothelioma (monitoring, early detection, and management).
- Improving personalization of therapies (gender and racial differences, targeted therapies, and predictive biomarkers).
- Mechanisms of treatment resistance/failure.
- Mesothelioma biology and etiology (disease-defining molecular pathways, cellular biology, and/or tumor microenvironment).
Applications will be submitted through the Grant Management Software.
